Cancer Genetics Company Profile (NASDAQ:CGIX)

About Cancer Genetics (NASDAQ:CGIX)

Cancer Genetics logoCancer Genetics, Inc. is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information. Its Select One Clinical Trials program provides a range of integrated and dynamic clinical trial services for both oncology and non-oncology genetic testing for Phase I-III trials along with ancillary services, including bioinformatics, biorepository and trials logistic support. The Company is developing a global footprint with locations in the United States, India and China. It also offers a portfolio of genotyping services, with access to over 400 validated genotyping assays, including Phase I and Phase II drug metabolizing enzymes, transporters, and receptors, and over 30 validated gene expression assays.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Healthcare Facilities & Services
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CGIX
  • CUSIP: N/A
  • Web: www.cancergenetics.com
Capitalization:
  • Market Cap: $56.4 million
  • Outstanding Shares: 19,790,000
Average Prices:
  • 50 Day Moving Avg: $3.40
  • 200 Day Moving Avg: $3.63
  • 52 Week Range: $1.10 - $5.30
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 96.67
  • P/E Growth: -0.10
Sales & Book Value:
  • Annual Revenue: $27.55 million
  • Price / Sales: 2.08
  • Book Value: $0.94 per share
  • Price / Book: 3.09
Profitability:
  • EBIDTA: ($11,120,000.00)
  • Net Margins: -68.48%
  • Return on Equity: -48.78%
  • Return on Assets: -26.29%
Debt:
  • Debt-to-Equity Ratio: 0.30%
  • Current Ratio: 2.40%
  • Quick Ratio: 2.40%
Misc:
  • Average Volume: 114,102 shs.
  • Beta: 1.24
  • Short Ratio: 18.42
 

Frequently Asked Questions for Cancer Genetics (NASDAQ:CGIX)

What is Cancer Genetics' stock symbol?

Cancer Genetics trades on the NASDAQ under the ticker symbol "CGIX."

How were Cancer Genetics' earnings last quarter?

Cancer Genetics, Inc. (NASDAQ:CGIX) announced its quarterly earnings results on Monday, August, 14th. The company reported ($0.16) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.16). The firm had revenue of $6.60 million for the quarter, compared to analysts' expectations of $7.97 million. Cancer Genetics had a negative return on equity of 48.78% and a negative net margin of 68.48%. The business's revenue was down 5.7% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.28) earnings per share. View Cancer Genetics' Earnings History.

Where is Cancer Genetics' stock going? Where will Cancer Genetics' stock price be in 2017?

4 brokers have issued 12 month price targets for Cancer Genetics' stock. Their forecasts range from $6.00 to $6.00. On average, they expect Cancer Genetics' share price to reach $6.00 in the next twelve months. View Analyst Ratings for Cancer Genetics.

Who are some of Cancer Genetics' key competitors?

Who are Cancer Genetics' key executives?

Cancer Genetics' management team includes the folowing people:

  • John G. Pappajohn, Chairman of the Board
  • Panna L. Sharma, President, Chief Executive Officer, Director, IR Contact Officer
  • John A. Roberts, Chief Financial Officer, Principal Financial Officer
  • Igor Gitelman CPA, Chief Accounting Officer, Principal Accounting Officer
  • Rita Shaknovich, Medical Director, Vice President - Hematopathology Services
  • Jane Houldsworth Ph.D., Vice President - Research & Development
  • Raju S. K. Chaganti Ph.D., Director
  • Geoffrey Eric Harris, Director
  • Edmund M. Cannon, Independent Director
  • Howard McLeod Pharm. D., Independent Director

Who owns Cancer Genetics stock?

Cancer Genetics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Perkins Capital Management Inc. (4.19%), Vanguard Group Inc. (2.62%), Fairbanks Capital Management Inc. (1.18%), Thompson Davis & CO. Inc. (0.56%), EAM Investors LLC (0.54%) and Wedbush Securities Inc. (0.31%). Company insiders that own Cancer Genetics stock include Edward J Sitar, Geoffrey E Harris, Igor Gitelman, John Pappajohn and Panna Sharma. View Institutional Ownership Trends for Cancer Genetics.

Who sold Cancer Genetics stock? Who is selling Cancer Genetics stock?

Cancer Genetics' stock was sold by a variety of institutional investors in the last quarter, including Wedbush Securities Inc., EAM Investors LLC and Perkins Capital Management Inc.. Company insiders that have sold Cancer Genetics stock in the last year include Edward J Sitar and Igor Gitelman. View Insider Buying and Selling for Cancer Genetics.

Who bought Cancer Genetics stock? Who is buying Cancer Genetics stock?

Cancer Genetics' stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Thompson Davis & CO. Inc. and Northern Trust Corp. Company insiders that have bought Cancer Genetics stock in the last two years include Geoffrey E Harris, Igor Gitelman, John Pappajohn and Panna Sharma. View Insider Buying and Selling for Cancer Genetics.

How do I buy Cancer Genetics stock?

Shares of Cancer Genetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cancer Genetics' stock price today?

One share of Cancer Genetics stock can currently be purchased for approximately $2.90.


MarketBeat Community Rating for Cancer Genetics (NASDAQ CGIX)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  116 (Vote Outperform)
Underperform Votes:  68 (Vote Underperform)
Total Votes:  184
MarketBeat's community ratings are surveys of what our community members think about Cancer Genetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Cancer Genetics (NASDAQ:CGIX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $6.00 (106.90% upside)

Analysts' Ratings History for Cancer Genetics (NASDAQ:CGIX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/21/2017HC WainwrightReiterated RatingBuy$6.00MediumView Rating Details
6/27/2017Dawson JamesInitiated CoverageBuyHighView Rating Details
6/26/2017Benchmark Co.Initiated CoverageSpeculative Buy$3.85 -> $6.00HighView Rating Details
9/26/2016Rodman & RenshawInitiated CoverageBuy$6.00N/AView Rating Details
3/15/2016AegisBoost Price TargetBuy$8.00 -> $15.00N/AView Rating Details
3/11/2016Janney Montgomery ScottReiterated RatingBuy -> NeutralN/AView Rating Details
(Data available from 9/22/2015 forward)

Earnings

Earnings History for Cancer Genetics (NASDAQ:CGIX)
Earnings by Quarter for Cancer Genetics (NASDAQ:CGIX)
Earnings History by Quarter for Cancer Genetics (NASDAQ CGIX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/14/2017Q2 2017($0.16)($0.16)$7.97 million$6.60 millionViewN/AView Earnings Details
5/11/2017Q1 2017($0.18)($0.11)$7.62 million$7.00 millionViewN/AView Earnings Details
3/23/2017Q4 2016($0.22)($0.15)$7.10 million$7.23 millionViewN/AView Earnings Details
11/10/2016Q316($0.28)($0.23)$6.93 million$6.80 millionViewN/AView Earnings Details
8/9/2016Q216($0.33)($0.28)$6.50 million$7.00 millionViewN/AView Earnings Details
5/10/2016Q1($0.43)($0.39)$6.95 million$6.10 millionViewListenView Earnings Details
3/10/2016Q415($0.46)($0.48)$7.00 million$5.50 millionViewListenView Earnings Details
11/10/2015Q315($0.49)($0.56)$5.13 million$4.00 millionViewListenView Earnings Details
8/11/2015Q215($0.50)($0.51)$4.67 million$4.20 millionViewListenView Earnings Details
5/12/2015Q115($0.54)($0.43)$3.91 million$4.40 millionViewListenView Earnings Details
3/12/2015Q414($0.52)($0.49)$3.70 million$4.00 millionViewN/AView Earnings Details
11/10/2014Q3 2014($0.51)($0.41)$3.11 million$3.22 millionViewN/AView Earnings Details
8/14/2014Q214($0.39)($0.50)$2.13 million$3.20 millionViewN/AView Earnings Details
5/15/2014Q114($0.29)($0.27)$2.17 million$1.40 millionViewN/AView Earnings Details
3/26/2014Q4 13($0.36)($0.37)$1.95 million$1.90 millionViewN/AView Earnings Details
11/13/2013Q313($0.71)($0.61)$1.60 million$1.70 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cancer Genetics (NASDAQ:CGIX)
2017 EPS Consensus Estimate: ($0.52)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.18)($0.18)($0.18)
Q2 20172($0.15)($0.14)($0.15)
Q3 20172($0.12)($0.12)($0.12)
Q4 20172($0.09)($0.05)($0.07)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cancer Genetics (NASDAQ:CGIX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Cancer Genetics (NASDAQ:CGIX)
Insider Ownership Percentage: 21.30%
Institutional Ownership Percentage: 16.08%
Insider Trades by Quarter for Cancer Genetics (NASDAQ:CGIX)
Institutional Ownership by Quarter for Cancer Genetics (NASDAQ:CGIX)
Insider Trades by Quarter for Cancer Genetics (NASDAQ:CGIX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/18/2017John PappajohnDirectorBuy86,185$3.24$279,239.40View SEC Filing  
8/17/2017John PappajohnDirectorBuy86,185$3.24$279,239.40View SEC Filing  
6/12/2017John PappajohnDirectorBuy100,000$3.75$375,000.00View SEC Filing  
5/25/2017Igor GitelmanInsiderBuy937$3.95$3,701.15View SEC Filing  
5/23/2017Igor GitelmanInsiderSell937$4.02$3,766.74View SEC Filing  
5/16/2017Geoffrey E HarrisDirectorBuy2,500$3.75$9,375.00View SEC Filing  
12/14/2016Geoffrey E HarrisDirectorBuy2,500$1.50$3,750.00View SEC Filing  
11/28/2016John PappajohnDirectorBuy100,000$1.45$145,000.00View SEC Filing  
11/16/2016Edward J SitarCFOSell3,333$1.56$5,199.48View SEC Filing  
11/14/2016John PappajohnDirectorBuy31,100$1.48$46,028.00View SEC Filing  
8/16/2016John PappajohnDirectorBuy45,000$2.29$103,050.00View SEC Filing  
8/15/2016John PappajohnDirectorBuy147,500$2.16$318,600.00View SEC Filing  
3/17/2016John PappajohnDirectorBuy50,000$2.64$132,000.00View SEC Filing  
3/17/2016Panna SharmaCEOBuy1,500$2.59$3,885.00View SEC Filing  
3/16/2016John PappajohnDirectorBuy100,000$2.53$253,000.00View SEC Filing  
3/15/2016Panna SharmaCEOBuy1,000$2.56$2,560.00View SEC Filing  
8/27/2015John PappajohnDirectorBuy5,000$9.61$48,050.00View SEC Filing  
6/25/2015Raju S.K. ChagantiDirectorSell5,296$12.00$63,552.00View SEC Filing  
6/12/2015Raju S.K. ChagantiDirectorSell7,000$12.01$84,070.00View SEC Filing  
6/11/2015Raju S.K. ChagantiDirectorSell46,454$12.03$558,841.62View SEC Filing  
6/8/2015Raju S.K. ChagantiDirectorSell24,583$12.03$295,733.49View SEC Filing  
5/14/2015John PappajohnDirectorBuy5,000$10.74$53,700.00View SEC Filing  
3/17/2015John PappajohnDirectorBuy50,000$7.36$368,000.00View SEC Filing  
3/16/2015Edward J SitarCFOBuy1,000$6.99$6,990.00View SEC Filing  
12/16/2014John PappajohnDirectorBuy5,589$6.20$34,651.80View SEC Filing  
12/15/2014John PappajohnDirectorBuy3,634$6.14$22,312.76View SEC Filing  
12/11/2014John PappajohnDirectorBuy27,087$6.03$163,334.61View SEC Filing  
12/10/2014John PappajohnDirectorBuy5,773$5.96$34,407.08View SEC Filing  
12/9/2014John PappajohnDirectorBuy39,686$5.35$212,320.10View SEC Filing  
5/21/2014Edward SitarCFOBuy1,000$10.67$10,670.00View SEC Filing  
5/21/2014John PappajohnDirectorBuy50,000$10.31$515,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Cancer Genetics (NASDAQ:CGIX)
Latest Headlines for Cancer Genetics (NASDAQ:CGIX)
Source:
DateHeadline
americanbankingnews.com logoFinancial Analysis: Cancer Genetics (CGIX) versus Its Rivals
www.americanbankingnews.com - September 22 at 2:20 AM
americanbankingnews.com logoHC Wainwright Reaffirms "Buy" Rating for Cancer Genetics, Inc. (CGIX)
www.americanbankingnews.com - September 21 at 8:56 PM
finance.yahoo.com logoCancer Genetics, Inc. Announces 25th Contract Win to Provide Testing & Diagnostic Services for Combination Immuno-Oncology Clinical Trial
finance.yahoo.com - September 20 at 5:53 PM
americanbankingnews.com logoCancer Genetics, Inc. (CGIX) Expected to Post Earnings of -$0.13 Per Share
www.americanbankingnews.com - September 10 at 6:24 PM
globenewswire.com logoCancer Genetics, Inc. Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference ... - GlobeNewswire (press release)
globenewswire.com - September 9 at 3:36 AM
nasdaq.com logoCancer Genetics, Inc. Announces Participation at the 19th Annual Rodman & Renshaw Global Investment
www.nasdaq.com - September 8 at 5:29 PM
finance.yahoo.com logoCancer Genetics, Inc. Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City, September 10-12, 2017
finance.yahoo.com - September 8 at 5:29 PM
americanbankingnews.com logoValuEngine Lowers Cancer Genetics, Inc. (CGIX) to Sell
www.americanbankingnews.com - September 3 at 7:08 PM
americanbankingnews.com logoCancer Genetics, Inc. (CGIX) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - September 1 at 10:32 PM
americanbankingnews.com logoAnalyzing Cancer Genetics (CGIX) and China Cord Blood Corporation (CO)
www.americanbankingnews.com - September 1 at 12:20 PM
americanbankingnews.com logoZacks: Brokerages Expect Cancer Genetics, Inc. (CGIX) Will Announce Quarterly Sales of $8.36 Million
www.americanbankingnews.com - August 25 at 1:22 PM
americanbankingnews.com logoZacks: Brokerages Expect Cancer Genetics, Inc. (CGIX) Will Post Earnings of -$0.12 Per Share
www.americanbankingnews.com - August 23 at 6:24 AM
finance.yahoo.com logoEarnings Review and Free Research Report: Quintiles IMS Reported Better than Expected Revenue and Earnings Results
finance.yahoo.com - August 22 at 10:43 PM
americanbankingnews.com logoInsider Buying: Cancer Genetics, Inc. (CGIX) Director Purchases 86,185 Shares of Stock
www.americanbankingnews.com - August 18 at 8:08 PM
americanbankingnews.com logoInsider Buying: Cancer Genetics, Inc. (CGIX) Director Acquires 86,185 Shares of Stock
www.americanbankingnews.com - August 18 at 8:08 PM
finance.yahoo.com logoCancer Genetics, Inc. to Host Conference Call to Discuss Strategic and Business Rationale of vivoPharm Acquisition
finance.yahoo.com - August 16 at 5:35 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Cancer Genetics and MiMedx Group
finance.yahoo.com - August 16 at 5:35 PM
feeds.benzinga.com logoCancer Genetics, Inc. to Host Conference Call to Discuss Strategic and Business Rationale of vivoPharm Acquisition
feeds.benzinga.com - August 16 at 7:43 AM
americanbankingnews.com logoCancer Genetics Inc (CGIX) Given a $6.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - August 15 at 6:40 PM
finance.yahoo.com logoEdited Transcript of CGIX earnings conference call or presentation 14-Aug-17 9:00pm GMT
finance.yahoo.com - August 15 at 5:51 PM
americanbankingnews.com logoCancer Genetics, Inc. (CGIX) Posts Earnings Results
www.americanbankingnews.com - August 15 at 9:41 AM
reuters.com logoBRIEF-Cancer Genetics reports Q2 loss per share $0.16
www.reuters.com - August 14 at 10:35 PM
nasdaq.com logoEarnings Reaction History: Cancer Genetics, Inc., 66.7% Follow-Through Indicator, 7.7% Sensitive - Nasdaq
www.nasdaq.com - August 14 at 5:33 PM
finance.yahoo.com logoCancer Genetics, Inc. Announces Second Quarter 2017 Financial Results, Accretive Acquisition and Capital Raise
finance.yahoo.com - August 14 at 5:33 PM
finance.yahoo.com logoCancer Genetics Announces Transformative and Accretive Acquisition of vivoPharm, a Global Oncology & Immuno-Oncology Discovery Services Company
finance.yahoo.com - August 14 at 5:33 PM
finance.yahoo.com logoCancer Genetics reports 2Q loss
finance.yahoo.com - August 14 at 5:33 PM
globenewswire.com logoCancer Genetics to Hold Second Quarter 2017 Earnings Call on Monday, August 14th - GlobeNewswire (press release)
globenewswire.com - August 9 at 2:57 AM
finance.yahoo.com logoCancer Genetics to Hold Second Quarter 2017 Earnings Call on Monday, August 14th
finance.yahoo.com - August 7 at 5:35 PM
americanbankingnews.com logo Brokerages Expect Cancer Genetics, Inc. (NASDAQ:CGIX) Will Announce Quarterly Sales of $8.35 Million
www.americanbankingnews.com - August 6 at 7:00 AM
americanbankingnews.com logoContrasting Cancer Genetics (CGIX) and HealthStream (HSTM)
www.americanbankingnews.com - August 4 at 12:28 PM
nasdaq.com logoDIA Elects Cancer Genetics, Inc.'s John A. (Jay) Roberts as Chairman of DIA Board of Directors - Nasdaq
www.nasdaq.com - August 3 at 6:43 PM
globenewswire.com logoDIA Elects Cancer Genetics, Inc.'s John A. (Jay) Roberts as ... - GlobeNewswire (press release)
globenewswire.com - August 3 at 6:43 PM
finance.yahoo.com logoDIA Elects Cancer Genetics, Inc.’s John A. (Jay) Roberts as Chairman of DIA Board of Directors
finance.yahoo.com - August 3 at 6:43 PM
finance.yahoo.com logoETFs with exposure to Cancer Genetics, Inc. : August 1, 2017
finance.yahoo.com - August 1 at 5:49 PM
nasdaq.com logoCancer Genetics, Inc. Acclaimed by Frost & Sullivan For North American Technology Innovation in Precision Oncology - Nasdaq
www.nasdaq.com - July 27 at 9:36 PM
finance.yahoo.com logoCancer Genetics, Inc. Acclaimed by Frost & Sullivan For North American Technology Innovation in Precision Oncology
finance.yahoo.com - July 27 at 4:35 PM
americanbankingnews.com logoCancer Genetics, Inc. (NASDAQ:CGIX) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - July 18 at 6:18 PM
americanbankingnews.com logoCancer Genetics, Inc. (CGIX) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - July 17 at 5:20 PM
americanbankingnews.com logoCancer Genetics, Inc. (CGIX) Expected to Post Quarterly Sales of $8.35 Million
www.americanbankingnews.com - July 15 at 7:50 AM
americanbankingnews.com logoCancer Genetics, Inc. (NASDAQ:CGIX) Expected to Post Earnings of -$0.16 Per Share
www.americanbankingnews.com - July 13 at 6:18 PM
americanbankingnews.com logoZacks Investment Research Downgrades Cancer Genetics, Inc. (NASDAQ:CGIX) to Sell
www.americanbankingnews.com - July 11 at 6:41 PM
finance.yahoo.com logoETFs with exposure to Cancer Genetics, Inc. : July 6, 2017
finance.yahoo.com - July 6 at 6:22 PM
americanbankingnews.com logoZacks Investment Research Downgrades Cancer Genetics, Inc. (CGIX) to Sell
www.americanbankingnews.com - July 5 at 5:34 PM
americanbankingnews.com logoCancer Genetics, Inc. Forecasted to Post Q2 2017 Earnings of ($0.14) Per Share (CGIX)
www.americanbankingnews.com - June 30 at 8:06 AM
streetinsider.com logoPre-Open Movers 06/27: (CGIX) (ARNA) (DRI) Higher; (ALDR) (FNJN) (NEOS) Lower (more...)
www.streetinsider.com - June 27 at 9:30 PM
streetinsider.com logoPre-Open Movers 06/27: (CGIX) (ARNA) (DRI) Higher; (ALDR) (FNJN) (NEOS) Lower (more...) - StreetInsider.com
www.streetinsider.com - June 27 at 4:30 PM
benzinga.com logoBenzinga's Top Upgrades, Downgrades For June 27, 2017 - Benzinga
www.benzinga.com - June 27 at 4:30 PM
nasdaq.com logoCancer Genetics, Inc. Launches FDA-Approved Universal Companion Diagnostic for Lung Cancer Leveraging Thermo ... - Nasdaq
www.nasdaq.com - June 27 at 4:30 PM
finance.yahoo.com logoCancer Genetics, Inc. Launches FDA-Approved Universal Companion Diagnostic for Lung Cancer Leveraging Thermo Fisher's Next Generation Sequencing Panel Oncomine Dx Target Test
finance.yahoo.com - June 27 at 4:29 PM
americanbankingnews.com logoCancer Genetics, Inc. (CGIX) Now Covered by Benchmark Co.
www.americanbankingnews.com - June 26 at 8:48 AM

Social

Chart

Cancer Genetics (CGIX) Chart for Friday, September, 22, 2017

This page was last updated on 9/22/2017 by MarketBeat.com Staff